Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00533910 · ClinicalTrials.gov registry record · NA
Rifaximin in Minimal Hepatic Encephalopathy
A NA study of Hepatic Encephalopathy, sponsored by Hunter Holmes Mcguire Veteran Affairs Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT00533910: Completed NA study of Hepatic Encephalopathy, sponsored by Hunter Holmes Mcguire Veteran Affairs Medical Center.
NCT00533910 is a NA study of Hepatic Encephalopathy that has completed, run by Hunter Holmes Mcguire Veteran Affairs Medical Center. The registered enrollment target is 42 participants, below the 173-participant average among 12 other Hepatic Encephalopathy trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00533910, a NA study of Hepatic Encephalopathy, has completed, sponsored by Hunter Holmes Mcguire Veteran Affairs Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether alteration of gut flora with rifaximin can lead to improvement in driving performance, psychometric test performance, and quality of life in patients with minimal hepatic encephalopathy (MHE) and cirrhosis in a randomized, blinded, placebo-controlled trial.
Primary Outcome
Total driving errors at the end of drug/placebo. Minimum is zero, maximum is not defined. Higher number indicates greater errors.
Conditions Studied
Interventions
- DRUG placebo
- DRUG Rifaximin
Study Locations (1)
Virginia
- Hunter Holmes McGuire VA Medical Center - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2007-10 |
| Est. Completion | 2010-05 |
| Phase | NA |
What the finished NCT00533910 record still lists
NCT00533910 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 173-participant average among 12 other Hepatic Encephalopathy trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Hepatic Encephalopathy appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00533910 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT00533910 about?
NCT00533910 is a clinical study titled "Rifaximin in Minimal Hepatic Encephalopathy". The purpose of this study is to determine whether alteration of gut flora with rifaximin can lead to improvement in driving performance, psychometric test performance, and quality of life in patients with minimal hepatic encephalopathy (MHE) and cirrhosis in a randomized, blinded, placebo-controlled...
What is the current status of trial NCT00533910?
This trial is currently completed. It is a NA study. The enrollment target is 42 participants. The study started on 2007-10. Estimated completion is 2010-05.
What conditions does trial NCT00533910 study?
This clinical trial studies the following conditions: Hepatic Encephalopathy.
What interventions are being tested in trial NCT00533910?
The interventions under investigation include: placebo (DRUG), Rifaximin (DRUG).
Who is sponsoring clinical trial NCT00533910?
This trial is sponsored by Hunter Holmes Mcguire Veteran Affairs Medical Center, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00533910 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatic Encephalopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00533910's enrollment target sits among peer trials
42 8th of 12 higher than 5 of 12 other Hepatic Encephalopathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatic Encephalopathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy
RECRUITING · NA
-
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
RECRUITING · NA
-
Affect of Melatonin on Sleep and Cognition in Cirrhosis
RECRUITING · NA
-
Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement
RECRUITING · Phase 2
-
TReatment for ImmUne Mediated PathopHysiology
RECRUITING · Phase 2
-
Fecal Microbiota Transplant as Treatment of Hepatic Encephalopathy
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia